Form 4: Delcath Systems Executive Acquires Shares Under Employee Stock Purchase Plan
SEC Form 4 Filing
Kevin Muir, GM of Interventional Oncology at Delcath Systems, reports acquiring 13,441 shares of common stock through the company's Employee Stock Purchase Plan.
Summary
- On March 19, 2024, Kevin Muir, GM of Interventional Oncology at Delcath Systems, acquired 13,441 shares of common stock.
- The shares were acquired at a price of $3.72 per share.
- This transaction increased Muir's direct holdings to 18,582 shares, which includes 5,141 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan.
Sentiment
Score: 6
Explanation: The sentiment is neutral as it reports a routine transaction. The executive's participation in the employee stock purchase plan could be viewed slightly positively.
Positives
- An executive's participation in the Employee Stock Purchase Plan can be seen as a positive sign of confidence in the company's future.
Industry Context
This Form 4 filing is a routine disclosure related to insider transactions and doesn't necessarily reflect broader industry trends.
Stakeholder Impact
- The transaction may have a minor positive impact on shareholder sentiment due to the executive's increased investment in the company.
Key Dates
| Date | Description |
|---|---|
| 03/19/2024 | Date of transaction: Kevin Muir acquired 13,441 shares of Delcath Systems common stock. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.